- Home
- ARCT vs MOLN Comparison
ARCT vs MOLN Comparison
Compare ARCT & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ARCT | MOLN |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 163.4M | 154.2M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ARCT | MOLN |
|---|---|---|
| Price | $8.23 | $4.21 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 2 |
| Target Price | ★ $24.11 | $8.38 |
| AVG Volume (30 Days) | ★ 503.7K | 976.0 |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $82,031,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.77 | $374.07 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.50 | $3.47 |
| 52 Week High | $24.14 | $5.36 |
Technical Indicators
Market Signals| Indicator | ARCT | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 70.86 | 57.37 |
| Support Level | $6.70 | $4.13 |
| Resistance Level | $8.97 | $4.30 |
| Average True Range (ATR) | 0.47 | 0.03 |
| MACD | 0.28 | 0.02 |
| Stochastic Oscillator | 91.07 | 90.47 |
Price Performance
Historical ComparisonAbout ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.